OSIMERTINIB DESTINE A ETRE UTILISE DANS LE TRAITEMENT DU CANCER DU POUMON NON A PETITES CELLULES

• 收藏
• 分享

专利权人:

ASTRAZENECA AB

发明人:

NASH, ANTHONY FRANCIS PATRICK

申请号：

CA3090010

公开号：

CA3090010A1

申请日:

2019.02.11

申请国别(地区):

CA

年份:

2019

代理人:

摘要：

The specification relates to osimertinib or a pharmaceutically acceptable salt thereof for use in the treatment of patients with locally advanced unresectable epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (Stage III)), and in particular to the treatment of patients whose disease has not progressed following definitive platinum-based chemoradiation therapy.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/